Recognition of Non-Operating Income and Expenses
ReproCELL Incorporated and its wholly owned subsidiary REPROCELL USA Inc.
Subsidies received by REPROCELL USA Inc., foreign-currency-denominated deposits and other assets held by the company, and the fundraising program
The subsidy income reflects receipt of the final payment following the achievement of prescribed milestones, among other factors. Foreign exchange gains and losses resulted from fluctuations in foreign exchange rates and the revaluation of foreign-currency-denominated deposits and other items. Share issuance costs comprised legal fees and other expenses incurred in connection with the fundraising program.
Subsidy income of ¥15 million (second quarter, non-operating income) and ¥105 million (cumulative interim period, non-operating income); foreign exchange loss of ¥15 million (second quarter, non-operating expense) and foreign exchange gain of ¥31 million (cumulative interim period, non-operating income); share issuance costs of ¥19 million (cumulative interim period, non-operating expense)
Interim consolidated accounting period of the fiscal year ending March 2027 (1 April 2026 to 30 September 2026). Part of the subsidy income and foreign exchange loss relates to the second-quarter consolidated accounting period (1 July 2026 to 30 September 2026).
For the impact on results and other effects of recording the non-operating income and expenses, refer to the "Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)" released today. The text does not state whether revisions were made or the revised figures.
For the impact on results and other effects, refer to the "Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)" released today.
| Item | Details |
|---|---|
| Event name | Recognition of Non-Operating Income and Expenses |
| Date of occurrence | 1 April 2026 to 30 September 2026 (interim consolidated accounting period; the second-quarter portions of subsidy income and foreign exchange losses relate to 1 July 2026 to 30 September 2026) |
| Subject Entity | ReproCELL Incorporated and its wholly owned subsidiary REPROCELL USA Inc. |
| Target Locations / Products | Subsidies received by REPROCELL USA Inc., foreign-currency-denominated deposits and other assets held by the company, and the fundraising program |
| Cause | The subsidy income reflects receipt of the final payment following the achievement of prescribed milestones, among other factors. Foreign exchange gains and losses resulted from fluctuations in foreign exchange rates and the revaluation of foreign-currency-denominated deposits and other items. Share issuance costs comprised legal fees and other expenses incurred in connection with the fundraising program. |
| Amount of Impact on Business Performance | Subsidy income of ¥15 million (second quarter, non-operating income) and ¥105 million (cumulative interim period, non-operating income); foreign exchange loss of ¥15 million (second quarter, non-operating expense) and foreign exchange gain of ¥31 million (cumulative interim period, non-operating income); share issuance costs of ¥19 million (cumulative interim period, non-operating expense) |
| Accounting period in which recognized | Interim consolidated accounting period of the fiscal year ending March 2027 (1 April 2026 to 30 September 2026). Part of the subsidy income and foreign exchange loss relates to the second-quarter consolidated accounting period (1 July 2026 to 30 September 2026). |
| Impact on Earnings Forecast | For the impact on results and other effects of recording the non-operating income and expenses, refer to the "Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)" released today. The text does not state whether revisions were made or the revised figures. |
| Outlook | For the impact on results and other effects, refer to the "Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)" released today. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The subsidy income reflects receipt of the final payment following the achievement of prescribed milestones by REPROCELL USA Inc., among other factors. Foreign exchange gains and losses resulted from fluctuations in foreign exchange rates and the revaluation of foreign-currency-denominated deposits and other items. Share issuance costs comprised legal fees and other expenses incurred in connection with the fundraising program.